Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • NPI Medicare & Medicaid
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.28
    OpenPayerBilling CodesDiseases and Disorders of the Skin, Subcutaneous Tissue and BreastDRG 607-minor-skin-disorders-without-mcc
    Ask Trek AI about this page

    Minor Skin Disorders without MCC: Inpatient Reimbursement Overview

    DRG 607 groups inpatient stays for minor skin and subcutaneous tissue disorders without Major Complication or Comorbidity, encompassing uncomplicated infections, minor excisions, and simple wound procedures. It matters for inpatient reimbursement because the Diagnosis-Related Group assignment establishes the Medicare payment bundle tied to expected resource use for these less complex skin conditions.

    Customize your policy alerts

    Sign up for drg 607 policy alerts

    Get alerted when payer policies referencing 607 are released or updated.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    DRG 607 Overview

    DRG 607 covers admissions for minor skin and subcutaneous tissue disorders without Major Complication or Comorbidity and typically includes conditions such as localized infections, simple skin grafts, and benign skin lesions requiring inpatient care. This Diagnosis-Related Group is relevant for Medicare payment because it defines a bundled payment rate based on the expected resource use for uncomplicated skin conditions. Hospitals use the DRG assignment to determine reimbursement under the inpatient prospective payment system. Accurate coding and documentation of comorbidities and procedures affect whether an admission qualifies for this DRG.

    Table of contents

    Progress1 / 3

    Explore openpayer tools

    • Billing CodesCPT, HCPCS, DRG & more
    • Reimbursement RatesCommercial vs. Medicare rate reports
    • ProvidersHospitals & facilities
    • PayersPlans & market footprint
    • Taxonomy CodesNUCC specialty codes
    • ModifiersCPT modifiers & usage
    • Prior AuthorizationPA policies by payer & drug
    • Timely FilingFiling deadlines by payer
    • Coverage CriteriaMedical necessity by payer
    • Payer ContactsClaims, PA & appeals contacts
    View all tools

    Clinical Trials

    • Acute wound-care and infection management trials: studies testing different topical antiseptics, short-course systemic antibiotics, or wound dressings for commonly hospitalized minor skin conditions (such as cellulitis limited to superficial tissues, infected ulcers without systemic signs, or acute contact dermatitis needing inpatient analgesia). These trials enroll adult or pediatric inpatients with minor skin disorders presenting for short-stay care and focus on rapid resolution of local inflammation, prevention of progression to deeper infection, and reductions in length of stay. Results are directly relevant to clinicians aiming to standardize initial inpatient treatment pathways and to payers seeking evidence to support cost-effective first-line regimens that minimize inpatient resource use and readmissions.
    • Comparative effectiveness studies of diagnostic and triage strategies: pragmatic trials or cohort studies comparing approaches such as bedside ultrasound assessment, dermatology consultation versus emergency physician management, or use of validated diagnostic algorithms for differentiating cellulitis from mimics (e.g., stasis dermatitis, eczema, or lipodermatosclerosis). These studies enroll patients admitted or evaluated for minor skin disorders whose diagnoses are uncertain and measure outcomes like diagnostic accuracy, time to appropriate therapy, inpatient length of stay, and downstream testing. Findings help hospitals and payers optimize triage, reduce unnecessary admissions and imaging, and allocate specialty consultation resources more efficiently.
    • Post-discharge outcomes and care-transition research: observational cohorts or randomized trials evaluating follow-up strategies (early outpatient dermatology or wound clinic visits, telehealth monitoring, or home nursing support) to prevent recurrence, monitor healing, and avoid readmission for patients discharged after treatment for minor skin conditions. These studies focus on patients discharged after short inpatient stays or observation, measuring rates of treatment failure, emergency revisits, patient-reported outcomes, and total 30- to 90-day costs of care. Evidence from this research informs discharge planning protocols and payer policies on coverage for post-discharge services that can reduce readmissions and overall expenditures.

    Related Codes

    570-SKIN-DEBRIDEMENT-WITH-MCC

    Skin Debridement with Major Complication or Comorbidity: Inpatient Reimbursement Overview

    571-SKIN-DEBRIDEMENT-WITH-CC

    Skin Debridement with CC: Inpatient Reimbursement Overview

    572-SKIN-DEBRIDEMENT-WITHOUT-CC-MCC

    Skin Debridement without CC/MCC: Inpatient Reimbursement Overview

    573-SKIN-GRAFT-FOR-SKIN-ULCER-OR-CELLULITIS-WITH-MCC

    Skin Graft for Skin Ulcer or Cellulitis with MCC: Inpatient Reimbursement Overview

    574-SKIN-GRAFT-FOR-SKIN-ULCER-OR-CELLULITIS-WITH-CC

    Skin Graft for Skin Ulcer or Cellulitis with CC: Inpatient Reimbursement Overview

    575-SKIN-GRAFT-FOR-SKIN-ULCER-OR-CELLULITIS-WITHOUT-CC-MCC

    Skin Graft for Skin Ulcer or Cellulitis without CC/MCC: Inpatient Reimbursement Overview

    576-SKIN-GRAFT-EXCEPT-FOR-SKIN-ULCER-OR-CELLULITIS-WITH-MCC

    Skin Graft Except for Skin Ulcer or Cellulitis with MCC: Inpatient Reimbursement Overview

    577-SKIN-GRAFT-EXCEPT-FOR-SKIN-ULCER-OR-CELLULITIS-WITH-CC

    Skin Graft Except for Skin Ulcer or Cellulitis with CC: Inpatient Reimbursement Overview

    578-SKIN-GRAFT-EXCEPT-FOR-SKIN-ULCER-OR-CELLULITIS-WITHOUT-CC-MCC

    Skin Graft Except for Skin Ulcer or Cellulitis without CC/MCC: Inpatient Reimbursement Overview

    579-OTHER-SKIN-SUBCUTANEOUS-TISSUE-AND-BREAST-PROCEDURES-WITH-MCC

    Other Skin, Subcutaneous Tissue and Breast Procedures with MCC: Inpatient Reimbursement Overview

    Showing 1–10 of 31

    References

    1. 1.CPT® Codes and Descriptions. AAPC. Retrieved Aug 11, 2026.Maintains the CPT code set's official descriptions and guidelines, licensed from the American Medical Association, used as the definitional source for CPT codes on this page.
    2. 2.HCPCS Quarterly Update. Centers for Medicare & Medicaid Services (CMS). Retrieved Aug 11, 2026.CMS's quarterly release of HCPCS Level II codes and short/long descriptors, the source for HCPCS code definitions and update history.
    3. 3.ICD-10-CM Full Code List. Centers for Medicare & Medicaid Services (CMS). Retrieved Aug 11, 2026.CMS's complete ICD-10-CM diagnosis code list, used to cross-reference diagnosis codes associated with this procedure or service.
    Published by

    Trek Health powers OpenPayer with a leading commercial payer intelligence platform, seamlessly converting fragmented payer data into actionable insights for provider organizations.

    Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.